By Ria Kakkad (Drug Target Review)2023-04-11T10:00:40
New research from Cincinnati Children’s Hospital Medical Center suggests blocking IL-22 and IL-1R could offer a promising IBD treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
2023-02-16T14:53:10
Sponsored by Cell Signaling Technology
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2024-05-07T13:11:19
Sponsored by BellBrook Labs
2025-04-22T14:58:00
Sponsored by Takara Bio USA
Site powered by Webvision Cloud